Skip to content
Guide

Is Compounded Semaglutide Safe? What to Ask a Med Spa

September 4, 2026 — what the newest federal FDA inspection records mean for compounded GLP-1s and peptides at clinics and med spas. Informational only — not medical advice.

Is compounded semaglutide safe? The honest answer: it depends on the facility that made the vial, not on the word “compounded.” A study published September 4, 2026, in the Journal of the American Pharmacists Association examined FDA records for 48 new compounding outsourcing facilities registered between January 1, 2020 and April 30, 2025. Only 11 — about 23 percent — had been inspected, and every inspected site had documented violations. If you are getting compounded semaglutide at a med spa or clinic, or weighing compounded tirzepatide or another peptide injection, those numbers are why the questions below matter more than the brochure on the counter.

Nothing in those records says compounding is automatically dangerous — or automatically safe. Compounding is how patients legally get a drug when an FDA-approved version is unavailable or unsuitable. The new analysis describes something narrower: how thinly the FDA has been able to inspect one category of large-scale compounders. If you are asking whether compounded GLP-1s are safe, the answer starts with those inspection records — and with the seven questions at the end of this guide.

What the September 4, 2026 analysis found

The study — McCall et al., “A quantitative and qualitative study of US FDA inspection reports of 503B outsourcing facilities,” J Am Pharm Assoc. 2026;66(5):103156 — counted federal inspection records, not patient outcomes.

11 of 48 newly registered facilities were inspected (about 23 percent)

The researchers identified 48 outsourcing facilities that registered with the FDA between January 1, 2020 and April 30, 2025 — including the GLP-1 shortage years, when compounding those drugs at scale was legal and booming. Only 11 (22.9 percent, about 23 percent) had been inspected. Roughly three-quarters of them — 37 of 48 — had not been inspected at all. That count is not a patient-harm rate, and it does not say the uninspected facilities were unsafe; it measures the size of an oversight gap.

Every inspected facility had violations

All 11 inspected facilities had at least two “significant objectionable findings” — a mean of 6.2 per site. The 68 findings fell into five recurring domains: quality control, personnel training, documentation, process validation, and product labeling. The most common problems matter most for sterile injectables: inadequate sterility testing, poor environmental controls, unvalidated production processes, and deficient recordkeeping.

More than two years between registration and inspection

Even inspections that happened came late: the mean gap between registration and inspection ran 2.2 years — more than two years — so facilities could ship sterile drugs for months before a federal inspector walked in. The authors describe “critical gaps” in oversight, with the greatest risk in sterile drug production.

What the study does not show

The analysis itself warns against the tempting misreading. FDA inspections are risk-prioritized, so the 11 inspected facilities are not a random sample of the 48; the violation finding describes what inspectors found where they looked, not every new facility. It also cannot say whether the gap narrowed since April 2025, whether violations were corrected, or whether any patient harm traces to an uninspected facility.

503B vs 503A: which compounding tier made your injection?

“Compounding pharmacy” covers two very different regulatory tiers, and most patients never learn which one made their vial.

503A pharmacies — patient-specific compounding under state oversight

Traditional compounding pharmacies operate under Section 503A of the federal Food, Drug, and Cosmetic Act. They fill patient-specific prescriptions, often one order at a time, and are overseen primarily by state boards of pharmacy rather than federal inspectors. When a clinic sends your prescription to a pharmacy that makes semaglutide with your name on the label, you are in the 503A world.

503B outsourcing facilities — bulk production under FDA registration

Outsourcing facilities, known as 503B compounders, were created by the Drug Quality and Security Act of 2013 — Congress’s response to the 2012 fungal meningitis outbreak, when contaminated steroid injections from a Massachusetts compounder killed dozens and sickened hundreds. They produce drugs in bulk, without patient-specific prescriptions, and ship them to hospitals, surgery centers, clinics, and medical spas. In exchange for scale they must register with the FDA and meet federal manufacturing standards — and they are meant to be inspected by the FDA. The 48 facilities in the September study are 503B facilities.

Which tier is behind the vial on the med-spa counter?

Most clinics and med spas do not compound anything in the back room. They buy finished product from one of the two tiers above, and the patient is rarely told which. It is legal for a med spa to stock product from an FDA-registered 503B facility, and legal for a 503A pharmacy to fill a patient-specific prescription a clinic forwards. The question is which facility made the product, whether it is registered and licensed, and what its inspection history looks like. For the full verification framework we apply to every pharmacy, see our 10-point compounding pharmacy verification checklist.

Why compounded GLP-1s are still in clinics — and under pressure

The market for compounded GLP-1s was built during the semaglutide and tirzepatide shortages, when compounding them at scale was legal and clinics stocked up. The shortage resolution and the Fifth Circuit ruling that ended bulk compounded GLP-1s have narrowed that legal path, and Novo Nordisk and Eli Lilly’s push to end compounded GLP-1s continues. But a patient offered compounded semaglutide today is still receiving a product made by one of the two tiers above — so the questions to ask are the same. The ingredient supply behind those products is a federal question too: twenty state attorneys general asked the White House to treat Chinese-sourced ingredients in compounded GLP-1 as a national-security problem.

The glutathione case: ingredient grade is not a detail

The oversight question stops being abstract with glutathione, a peptide sold at med spas for IV “wellness” drips. The FDA has told compounders not to use dietary supplement-grade glutathione in injectables, reporting at least 30 adverse events after glutathione injections. Two Texas compounding pharmacies recalled product over elevated endotoxin levels — including the 14-state glutathione injection recall we covered in August — and the FDA said both obtained the ingredient, labeled dietary supplement grade, from the same supplier. Both operate on the 503A pathway, overseen by state boards rather than federal inspectors — a different tier than the 503B facilities in the study.

The lesson is not that glutathione is dangerous. It is that “compounded” tells you nothing about ingredient grade, sterility, or oversight — and those details are askable.

What to ask before getting a compounded GLP-1 or peptide

If you are asking “are compounded peptides safe?”, the reply is that the question is about the facility, not the category. These seven questions turn that into a conversation a front desk can answer:

1. Is this product FDA-approved or compounded?
If FDA-approved, most of what follows is moot. If compounded, the next six answers determine your risk picture.

2. Which facility prepared it — 503A or 503B?
Get the name of the actual compounding facility, not “our pharmacy partner.” Then ask whether it is a 503A pharmacy compounding your prescription under state oversight, or a 503B facility producing in bulk under FDA registration.

3. Is the facility registered and licensed?
503B facilities must be registered with the FDA; 503A pharmacies must be licensed by the state board where they operate. Ask for the number, then look it up — both are public record.

4. What does its inspection history look like?
The FDA publishes warning letters, and recall databases are public. Ask about findings, warning letters, or recalls — and do not assume a registered 503B facility has been inspected; only about 23 percent of newly registered facilities in the study window had been.

5. What sterile compounding practices does it follow?
Ask about sterility testing, environmental monitoring, and endotoxin testing of finished product. Written answers matter more than assurances.

6. What is in the batch, and where did the ingredients come from?
Ask whether ingredients are pharmaceutical grade — not dietary supplement grade, the glutathione distinction — and ask for the lot number, batch records, and beyond-use date. If the clinic cannot produce a lot number, that is an answer in itself.

7. How was this prescribed and sold — and what should I watch for after?
A compounded product should trace to a patient-specific prescription from a licensed prescriber. Ask what follow-up looks like, and what symptoms should prompt a call: fever, chills, worsening pain, redness or swelling at the injection site, or feeling unwell in the hours after an injection.

The fine print: who wrote the study, and the caveats you deserve

The lead author, Kenneth L. McCall, PharmD, serves on the board of the Partnership for Safe Medicines, an advocacy organization whose members include pharmaceutical manufacturers and which campaigns for tighter controls on drug supply and compounding. The underlying inspection data are federal records; the framing comes from a group with a declared position in this debate. That does not invalidate the numbers — it is context a reader is entitled to have. The mirror-image caveat applies to manufacturers pushing to end compounding, which is why this guide leans on primary records rather than on either side’s conclusion.

The honest bottom line

Compounding solves real problems: child-safe liquids, allergen-free formulations, and needed drugs when no commercial version is available. What the September 2026 study shows is that the oversight system for one category of compounders has real gaps — infrequent inspections, delays of more than two years, and violations at every site inspectors reached.

No responsible reading concludes that all compounding is unsafe — and no responsible buyer ignores what the records show. If you are considering compounded semaglutide, tirzepatide, or any peptide injection at a clinic or med spa, use the seven questions above, verify the facility against public records, and take medical questions to the licensed prescriber.

Frequently asked questions

Is compounded semaglutide safe?

It depends on the facility that made it. A September 4, 2026 analysis of FDA records found that only 11 of 48 (about 23 percent) newly registered 503B outsourcing facilities were inspected between January 2020 and April 2025, and every inspected site had documented violations. Compounded semaglutide from a registered, inspected, well-documented facility is a different proposition than product from an uninspected one.

Is compounded tirzepatide safe?

The same answer applies as for semaglutide: safety tracks the facility, not the molecule. The September 2026 analysis covered 503B outsourcing facilities generally rather than any single drug, and its findings — infrequent inspections, delays of more than two years, and violations at every inspected site — apply to whatever sterile product a facility makes, including compounded tirzepatide.

What is a 503B facility vs a 503A pharmacy?

A 503A pharmacy is a traditional compounding pharmacy that fills patient-specific prescriptions and is overseen primarily by state pharmacy boards. A 503B outsourcing facility produces drugs in bulk without patient-specific prescriptions, registers with the FDA, and is subject to federal manufacturing standards and federal inspection. Clinics and med spas may source from either tier.

How often does the FDA inspect 503B facilities?

In the September 2026 JAPhA analysis, only 11 of 48 (about 23 percent) 503B facilities newly registered between January 1, 2020 and April 30, 2025 had been inspected, and the average gap between registration and inspection was 2.2 years — more than two years.

What should I ask a med spa before getting compounded GLP-1s or peptides?

Ask the seven questions in this article: whether the product is FDA-approved or compounded; which facility made it and whether it is a 503A pharmacy or 503B outsourcing facility; whether it is registered and licensed; what its inspection history looks like; what sterile compounding and testing practices it follows; ingredient grade and batch information; and how the product was prescribed plus what to watch for afterward.

What happened in the glutathione recalls?

The FDA told compounders not to use dietary supplement-grade glutathione in injectables after at least 30 patients experienced adverse events. Two Texas compounding pharmacies — both on the 503A pathway — issued recalls over elevated endotoxin levels, and the FDA said both obtained the ingredient, labeled as dietary supplement grade, from the same supplier.

Are compounded peptides safe?

Sometimes yes — compounding is legal and sometimes necessary, and many licensed pharmacies do it well. The September 2026 study does not show that compounding is inherently unsafe; it shows the FDA inspected only about 23 percent of newly registered 503B facilities in the study window and found violations at every site it did inspect. The safety question is facility-specific.

Sources

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.